● HRS-4729治疗12周后，参与者平均体重较基线降幅最高达16.0%，并可降低肝脏脂肪含量 ● HRS-4729的安全性与耐受性特征与现有GLP-1类药物类似 ● 恒瑞医药计划在中国推进HRS-4729的多项Ⅱ期临床试验，Kailera计划于2026年启动全球Ⅰ期临床试验，预计2027年获得数据 2026年5月27日，恒瑞医药与美国Kailera Therapeutics公司(Kailera)共同宣布，GLP-1/GIP/GCG三重受体激动剂HRS-4729注射液（大中华区外称KAI-4729）在中国健康参与者中开展的Ⅰ期首次人体临床试验（HRS-4729-101）取得积极顶线数据1。在Ⅰ期多次剂量递增（MAD）试验中，HRS-4729组平均体重较基线降幅最高达16.0%，并可降低肝脏脂肪含量，安全性和耐受性特征与现有GLP-1类药物类似。 本试验分为单次剂量递增（SAD）和多次剂量递增（MAD）两部分。研究结果显示： ● HRS-4729表现出线性药代动力学特征，半衰期约为4至5天，支持每周一次给药； ● 给药12周后，HRS-4729 12 mg组平均体重较基线降幅达16.0

Reviewed by Dr. Angela Tran, MD, board-certified in internal and obesity medicine, Chief Medical Advisor at Sunlight. KIRKLAND, Wash., May 26, 2026 /PRNewswire/ -- Sunlight NAD+ Rx, the company's new compounded NAD+ injection program, starts at $125 per month on the annual plan, is delivered through the Sunlight Clinical Pathway, and arrives as a recent survey from the company finds 1 in 7 U.S. peptide users have bought from Telegram, WhatsApp, or social media sellers without clinician oversig

Milestone EIA clearance brings Binaytara one step closer to starting construction on the 200-bed facility, which will serve a catchment population of 25 million across southern Nepal and northern India. JANAKPUR, Nepal, May 26, 2026 /PRNewswire/ -- Binaytara, a global oncology nonprofit working to eliminate cancer disparities, today announced that the Government of Nepal has granted Environmental Impact Assessment (EIA) approval for the construction of the Binaytara Cancer Hospital, a $30 millio

//   • 优赫得已连续三年成为ADC销冠，销售额断层领先； • 第一三共凭借DXd ADC技术成为2025年世界ADC大奖评选最大赢家； • 第一三共正逐渐摆脱传统综合药企“泛而不精”的标签，提出2035年跻身全球肿瘤药企前五的战略目标。 2021年，Nature的一篇文章预测，2026年ADC明星产品优赫得（Enhertu）将以62亿美元销售额登顶全球ADC市场。今年，预期目标能否实现？ 据第一三共最新发布的财报预测，2026年优赫得的销售额预计约为8613亿日元（54.15亿美元），同比增长23.3%，加上潜在的6.25亿美元销售里程碑付款，总额将超60亿美元。 当前，在全球ADC市场，头部集中态势明显，TOP3产品合计占市场份额超60%，优赫得的销售额呈现断层领先。2025年优赫得的全球销售额为6984亿日元（43.91亿美元），加上5.375亿美元的销售里程碑付款，总额接近第二名罗氏的Kadcyla和第三名安斯泰来/辉瑞的Padcev销售额的总和。事实上，从2023年开始，优赫得的销售额就超过了Kadcyla，成为ADC销冠。 在第一三共的DXd ADC管线中，另一款重磅产

SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair 46 th Annual Growth Stock Conference. Fireside chat on Tuesday, June 2, 2026 at 10:40 AM CT (11:40 AM ET) in Chicago Goldman Sachs 47 th Annual Global Healthcare Conference 2026. Fireside chat on Tuesday, June 9, 2026 at 9:20 AM ET in Miami The webcasts can also be accessed on Neurocrine Biosciences' websit

Company advances multiple trials evaluating wound care innovations and imaging technologies PHOENIX, May 26, 2026 /PRNewswire/ -- BioLab Holdings, Inc., a Phoenix-based medical technology company focused on advancing tissue restoration through innovation, strategic partnerships, and commercialization, announced significant progress across its portfolio of clinical trials designed to demonstrate the safety and efficacy of its Cellular, Acellular and Matrix-like Products (CAMPs), as well as its e

SAN DIEGO, May 26, 2026 /PRNewswire/ -- Today, the national food poisoning law firm of Ron Simon & Associates, along with The Gomez Trial Attorneys, filed the first lawsuit against The Kebab Shop and Olympia Foods in Orange County, California. A copy of the lawsuit is available upon request. “E. coli O157:H7 is uniquely dangerous to children, with the potential to cause life-threatening Hemolytic Uremic Syndrome, which is exactly what KG developed. Any consumer who ate at The Kebab in late Ma

BALTIMORE, May 26, 2026 /PRNewswire/ -- The Journal of Clinical Psychiatry recently published results from a clinical trial conducted at Sheppard Pratt, examining the efficacy and safety of psilocybin-assisted therapy for individuals experiencing chronic suicidal ideation and treatment-resistant depression. The study, led by Scott T. Aaronson, MD, chief science officer at Sheppard Pratt with Andrew van der Vaart, MD, PhD, psychiatrist at Sheppard Pratt, as first author, provides early evidence t

BUCHAREST, Romania, May 26, 2026 /PRNewswire/ -- MONZA-ARES, a leading Romanian private hospital group focused on cardiology and complex surgery, and Brain Institute, the country's premier private neurosurgery center, today announced they are combining operations to create one of Romania's leading private healthcare platforms. The joint group is backed by U.S.-based private equity firm Highlander Partners and will focus on complex surgical procedures and high-acuity care across cardiology, neuro

MaaT013 (Xervyteg ® ): In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), ahead of the expected CHMP formal vote in June; the Company plans to request a re-examination procedure upon the formal opinion EBMT 2026 annual congress: MaaT Pharma presented data from the pivotal ARES trial of MaaT013 (Xervyteg ® ) featured in the Presidential